Current Progress in Dengue Vaccine Clinical Trial

Wei Chung, I-An Chen, Jen-Ron Chiang

2015 Vol.31 NO.8

Correspondence Author: Wei Chung

  • Center for Research, Diagnostics and Vaccine Development, Centers for Disease Control, Ministry of Health


Dengue is one of the most important vector-borneviral diseases. Global phenomena such as urbanization and international travelare key factors in facilitating the spread of dengue causing major publichealth problems worldwide. There are four serotypes of dengue viruses (DENV),each serotype of DENV is capable of causing self-limited dengue fever (DF) ordengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) by a relativelyhigh mortality rate and/or high sequelae rate in survivors. No cure for dengueexists; treatment is limited to rehydration therapy, and with vector controlstrategies proving to be relatively ineffective. Moreover dengue life cyclesare maintained between arthropod vectors and amplifying/reservoir hosts in theabsence of humans, eradication of dengue might be extremely difficult. Sovaccine development is considered a reasonable method to prevent dengueinfections. In this article, we summarize the current dengue vaccine candidatesin clinical trials, and discuss the directions and problems in vaccines development.

Keywords:Dengue;tetravalent;vaccine introduction